Viridian Therapeutics, Inc. VRDN Unrealized Losses on Investments (Before Tax)
Unrealized Losses on Investments (Before Tax) at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s unrealized losses on investments (before tax).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s unrealized losses on investments (before tax)?
- Viridian Therapeutics, Inc. (VRDN) reported unrealized losses on investments (before tax) of $612K in Q1 2026.
- How has Viridian Therapeutics, Inc.'s unrealized losses on investments (before tax) changed year-over-year?
- Viridian Therapeutics, Inc.'s unrealized losses on investments (before tax) increased by 120.1% year-over-year, from $278K to $612K.
- What is the long-term trend for Viridian Therapeutics, Inc.'s unrealized losses on investments (before tax)?
- Over 4 years (2021 to 2025), Viridian Therapeutics, Inc.'s unrealized losses on investments (before tax) has grown at a -26.3% compound annual growth rate (CAGR), from $163K to $48K.